Redmont Capital

Redmont Capital, established in 1998 and headquartered in Birmingham, Alabama, is an investment banking firm that provides comprehensive compliance services to its advisory clients. These services include tax preparation, sales tax filings, and financial statement preparation. Additionally, the firm engages in investment activities, focusing on mezzanine funding, senior debt, subordinated debt, and equity investments. Redmont Capital targets companies operating in commercial services, financial services, healthcare, information technology, manufacturing, and industrial sectors within Southwest Texas and the Central Southeast region of the United States.

Philip Hodges

Co-Founder and Managing Partner

Douglas C. Sellers

Managing Director

Jessica Thomason

Senior Vice President

4 past transactions

Wenzel Spine

Series B in 2016
Wenzel Spine, Inc. is a medical technology company dedicated to developing innovative diagnostic and minimally invasive surgical solutions for spinal disorders. By focusing on advanced medical devices, the company aims to enhance the quality of spine care through simplified procedures and reduced recovery times. Wenzel Spine's surgical systems are designed to empower surgeons in their treatment efforts, ultimately facilitating quicker recovery for patients while improving overall outcomes in spinal care.

Altimmune

Post in 2015
Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative treatments for liver disease, obesity, and vaccines. The company’s pipeline includes HepTcell, an immunotherapeutic candidate for chronic hepatitis B, which has successfully completed Phase I clinical trials. Altimmune also develops NasoShield, an intranasal anthrax vaccine, and NasoVAX, a recombinant intranasal vaccine. Additionally, the company is advancing AdCOVID, a single-dose intranasal vaccine for COVID-19. In the preclinical stage, Altimmune is working on ALT-801, a peptide-based dual GLP-1/glucagon receptor agonist for non-alcoholic steatohepatitis, as well as ALT-702, a tumor immunostimulant aimed at cancer treatment. The company employs proprietary technology for non-invasive intranasal delivery of its products and collaborates with institutions such as the University of Alabama at Birmingham to further its research initiatives.

EnteGreat

Venture Round in 2008
EnteGreat, Inc., established in 2000 and headquartered in Vestavia Hills, Alabama, specializes in operational excellence for manufacturers across various industries. The company offers consulting services and specialized applications focused on manufacturing intelligence solutions. Their key offerings include enCONTEXTTM, a SaaS platform for manufacturing analytics; Manufacturing Value Framework solutions such as Compliant Manufacturing Framework and energy management solutions; and industry-specific consulting services. EnteGreat helps clients address manufacturing and supply chain management issues through expert guidance and tailored solutions.

Emageon

Series B in 2000
Emageon is a provider of enterprise-level information technology solutions focused on the clinical analysis and management of digital medical images within healthcare organizations. The company specializes in developing software products that enable physicians and healthcare professionals to efficiently manage, access, and visualize multi-specialty medical content. Emageon's offerings include advanced visualization tools, clinical content management systems, and workflow solutions designed to enhance the efficiency and effectiveness of medical imaging processes in various healthcare settings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.